Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses' Health Study (United States)

1995 ◽  
Vol 6 (3) ◽  
pp. 217-224 ◽  
Author(s):  
Susan E. Hankinson ◽  
Graham A. Colditz ◽  
David J. Hunter ◽  
JoAnn E. Manson ◽  
Walter C. Willett ◽  
...  
2006 ◽  
Vol 17 (6) ◽  
pp. 843-850 ◽  
Author(s):  
Anthony B. Crest ◽  
Erin J. Aiello ◽  
Melissa L. Anderson ◽  
Diana S. M. Buist

2019 ◽  
Author(s):  
hanlu gao ◽  
Chao Yang ◽  
Jinqing Fan ◽  
Li Lan ◽  
Da Pang

Abstract Background: Family history of breast cancer and female reproductive factors may work together to influence hyperplasia of mammary gland (HMG) risk. However, the association with HMG risk is poorly characterized and might be important to understand the causation of HMG.Methods: A total of 1881 newly diagnosed HMG cases and 1900 controls were recruited between 2012 and 2017. We collected each participant's demographic characteristics, female reproductive factors and family history of breast cancer. A multi-analytic strategy combining unconditional logistic regression, multifactor dimensionality reduction (MDR) and crossover approaches were applied to systematically identify the interactions of family history of breast cancer and reproductive factors on HMG susceptibility.Results: In MDR analysis, high-order interactions among education level, breastfeeding duration and family history of breast cancer were identified among women (OR=7.069, 95%CI: 6.080-8.219). Similarly, in crossover analysis, compared with individuals having low education level and no family history of breast cancer, HMG risk increased significantly for those having high education level and family history of breast cancer (OR=36.389, 95%CI: 11.469-115.451), similar additive interaction effect was observed among short breastfeeding duration women (OR=27.699, 95%CI: 3.730-205.699).Conclusion: This study suggests high-order interactions of high education level, short breastfeeding duration and family history of breast cancer may synergistically increased HMG risk.


2016 ◽  
Vol 27 ◽  
pp. iv59 ◽  
Author(s):  
A. Toss ◽  
G. Grandi ◽  
S. Pavesi ◽  
L. Marcheselli ◽  
E. De Matteis ◽  
...  

Author(s):  
Hanlu Gao ◽  
Chao Yang ◽  
Jinqing Fan ◽  
Li Lan ◽  
Da Pang

Abstract Background Hyperplasia of mammary gland (HMG) has become a common disorder in women. A family history of breast cancer and female reproductive factors may work together to increase the risk of HMG. However, this specific relationship has not been fully characterized. Methods A total of 1881 newly diagnosed HMG cases and 1900 controls were recruited from 2012 to 2017. Demographic characteristics including female reproductive factors and a family history of breast cancer were collected. A multi-analytic strategy combining unconditional logistic regression, multifactor dimensionality reduction (MDR) and crossover approaches were applied to systematically identify the interaction effect of family history of breast cancer and reproductive factors on HMG susceptibility. Results In MDR analysis, high-order interactions among higher-level education, shorter breastfeeding duration and family history of breast cancer were identified (odds ratio [OR] 7.07 [95% confidence interval {CI} 6.08 to 8.22]). Similarly, in crossover analysis, HMG risk increased significantly for those with higher-level education (OR 36.39 [95% CI 11.47 to 115.45]), shorter duration of breastfeeding (OR 27.70 [95% CI 3.73 to 205.70]) and a family history of breast cancer. Conclusion Higher-level education, shorter breastfeeding duration and a family history of breast cancer may synergistically increase the risk of HMG.


Author(s):  
Trevor J Powles ◽  
Anthony Howell ◽  
D Gareth Evans ◽  
Eugene V Mccloskey ◽  
Sue Ashley ◽  
...  

Objective To assess the safety and tolerability of a standardized 40 mg red clover isoflavone dietary supplement (Promensil®, Novogen) in women with a family history of breast cancer to evaluate the feasibility of using the supplement for prevention of breast cancer in healthy women. Study design Healthy women aged 35–70 years (n = 401) with at least one first-degree relative with breast cancer received red clover isoflavones or placebo for three years in a randomized, double-blind, placebo-controlled pilot trial. Participants were assessed clinically and blood samples taken for biochemical analysis every six months. In addition, study participants underwent mammography, bone density and transvaginal ultrasound (postmenopausal women only) once per year. Results No significant differences in breast density, endometrial thickness, serum cholesterol, follicle stimulating hormone levels and bone mineral density were detected between those taking red clover isoflavones and placebo. In postmenopausal women, some significant differences in bone marker levels were seen between active and placebo groups, at six months and at 12 months. The adverse event profile was similar across all red clover isoflavone and placebo groups. Conclusion This three-year study supports the growing body of evidence that treatment with red clover isoflavones is safe and well tolerated in healthy women. Supplements containing red clover isoflavones did not adversely affect breast density, skeletal strength or cardiovascular status. In postmenopausal women, endometrial status was not adversely affected. The adverse event profile was similar between red clover isoflavones, and placebo and endocrine status did not differ.


Author(s):  
Angelina Sontag ◽  
Lawrence Wickerham ◽  
Xiao Ni ◽  
Beth D. Mitchell ◽  
Cameron Helt ◽  
...  

2010 ◽  
Vol 12 (5) ◽  
Author(s):  
Robert Gramling ◽  
Timothy L Lash ◽  
Kenneth J Rothman ◽  
Howard J Cabral ◽  
Rebecca Silliman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document